CVI Holdings’s Revelation Biosciences Warrant REVBW Stock Holding History

CVI Holdings’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-294,500	Closed	-$200K	–	951
2021 Q4	$200K	Sell	294,500 -5,500	-2%	-$3.37K	0.01%	527
2021 Q3	$183K	Hold	300,000	–	–	0.01%	536
2021 Q2	$192K	Hold	300,000	–	–	0.01%	487
2021 Q1	$156K	Buy	+300,000	New	+$280K	0.01%	441

Other funds holding REVBW

OCAM

Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Capstone Investment Advisors New York $54B AUM 23.5% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

CVI Holdings's REVBW Position: Q1 2022 in Review

CVI Holdings sold out of Revelation Biosciences Warrant (REVBW) in Q1 2022, closing a stake of 294,500 shares — an estimated $200K sold.

CVI Holdings first reported a position in REVBW in Q1 2021 and held it in 4 quarters. The position peaked at $200K in Q4 2021. 18 funds tracked by Wall St. Rank hold REVBW as of Q1 2022.

CVI Holdings reported no remaining Revelation Biosciences Warrant position as of Q1 2022 after selling out during the quarter.
CVI Holdings sold 294,500 Revelation Biosciences Warrant shares in Q1 2022, an estimated $200K.
CVI Holdings first reported a position in Revelation Biosciences Warrant in Q1 2021 and held it in 4 quarters.
CVI Holdings's Revelation Biosciences Warrant position peaked at $200K in Q4 2021.
18 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q1 2022.

Based on CVI Holdings's 13F filing for Q1 2022, filed 16 May 2022.